Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 3 1

Status

Active not recruiting 2Completed 1

Sponsor Class

OTHER 3INDUSTRY 3NETWORK 1

Study Type

Interventional 3Observational 2Expanded_access 1

Sponsor

Cancer Type

CNS 2

Conditions

Oligodendroglioma 1Healthy Adult Participants 1Glioma 1Astrocytoma 1

Interventions

pembrolizumab 1023Carboplatin 964Paclitaxel 933Gemcitabine 794Cisplatin 751Docetaxel 683Bevacizumab 609Pemetrexed 502Nivolumab 487Cyclophosphamide 471Capecitabine 461Fluorouracil 418Dexamethasone 403Rituximab 372Oxaliplatin 348Injections 345atezolizumab 298Trastuzumab 298Leucovorin 288Cetuximab 282Irinotecan 268130-nm albumin-bound paclitaxel 254Prednisone 245Doxorubicin 240Ipilimumab 226Lenalidomide 220fludarabine 218Fulvestrant 217durvalumab 205Erlotinib Hydrochloride 188

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Interventional × vorasidenib × Clear all
NCT05484622 2026-03-12

Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive IDH-1 Mutant Glioma

Servier

Phase 1 Active not recruiting
60 enrolled
CNS

Astrocytoma, Oligodendroglioma

NCT07235748 2026-02-17

Drug-drug Interaction Study of Vorasidenib With Bupropion, Repaglinide, Flurbiprofen, Omeprazole, Midazolam, and Rosuvastatin in Healthy Adult Participants

Servier

Phase 1 Completed
28 enrolled

Healthy Adult Participants

NCT04164901 2025-04-03

Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO)

Servier

Phase 3 Active not recruiting
331 enrolled 25 charts 1 FDA
CNS

Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡